Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement.

Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F.

J Rheumatol. 2013 Jan;40(1):52-7. doi: 10.3899/jrheum.120778. Epub 2012 Nov 1.

PMID:
23118116
2.

Assessment of sensitivity to change of the European Scleroderma Study Group activity index.

Melsens K, De Keyser F, Decuman S, Brusselle G, De Pauw M, Deschepper E, De Wilde K, Elewaut D, Piette Y, Vandecasteele E, Smith V.

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):148-151. Epub 2016 Jul 18.

PMID:
27463733
3.

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.

Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, Carreira PE, Diaz Gonzalez F, Black CM, van den Hoogen FH.

Ann Rheum Dis. 2009 Sep;68(9):1433-9. doi: 10.1136/ard.2008.096123. Epub 2008 Sep 9.

PMID:
18782794
4.

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.

Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F.

Ann Rheum Dis. 2010 Jan;69(1):193-7. doi: 10.1136/ard.2008.095463.

PMID:
19103636
5.

B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin.

Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP.

Arthritis Res Ther. 2012 Jun 14;14(3):R145. doi: 10.1186/ar3879.

6.

Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.

Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, De Langhe E, De Pauw M, Debusschere C, Decuman S, Deroo L, Houssiau F, Lenaerts J, Piette Y, Thevissen K, Vanthuyne M, Westhovens R, Wijnant S, De Keyser F, Smith V.

Acta Clin Belg. 2017 Sep 11:1-7. doi: 10.1080/17843286.2017.1372244. [Epub ahead of print]

PMID:
28891418
7.

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW.

Arthritis Rheum. 2009 Feb;60(2):578-83. doi: 10.1002/art.24249.

8.

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

McQueen FM, Solanki K.

Rheumatology (Oxford). 2015 May;54(5):757-67. doi: 10.1093/rheumatology/keu463. Epub 2015 Jan 7. Review.

PMID:
25573841
9.

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.

Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; EUSTAR Rituximab study group.

Ann Rheum Dis. 2015 Jun;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522. Epub 2014 Jan 17.

PMID:
24442885
10.

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.

Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, Crow MK, Whitfield ML, Spiera RF.

Arthritis Res Ther. 2015 Aug 18;17:213. doi: 10.1186/s13075-015-0721-3.

11.

A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G.

Arthritis Rheum. 2012 Mar;64(3):843-53. doi: 10.1002/art.34331.

12.

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, Sica G, Ferraccioli G.

Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965. Epub 2010 Mar 25.

13.

Rituximab in psoriatic arthritis: an exploratory evaluation.

Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayová H, Leeb B, Machold KP, Graninger WB, Smolen JS.

Ann Rheum Dis. 2012 Nov;71(11):1868-71. doi: 10.1136/annrheumdis-2012-201897. Epub 2012 Jul 24.

PMID:
22833373
14.

Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register.

J Rheumatol. 2012 Feb;39(2):240-6. doi: 10.3899/jrheum.110610. Epub 2011 Dec 15.

15.

Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.

Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP; RESET Investigators.

J Rheumatol. 2011 Dec;38(12):2548-56. doi: 10.3899/jrheum.110444. Epub 2011 Oct 1.

16.

Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.

Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E, Ruocco L.

Scand J Rheumatol. 2006 Jan-Feb;35(1):35-8.

PMID:
16467039
17.

Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.

Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S17-22. Epub 2012 May 29.

PMID:
22244622
18.

Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.

Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G.

Semin Arthritis Rheum. 2015 Feb;44(4):428-36. doi: 10.1016/j.semarthrit.2014.09.002. Epub 2014 Sep 8.

PMID:
25300701
19.

Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.

Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Semin Arthritis Rheum. 2011 Dec;41(3):401-5. doi: 10.1016/j.semarthrit.2011.06.005. Epub 2011 Aug 20.

PMID:
21862107
20.

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X.

Ann Rheum Dis. 2007 Mar;66(3):351-7. Epub 2006 Sep 1.

Supplemental Content

Support Center